The company is substantially advanced its course of an new therapy for ATTR-CM, utilizing the compound. Early trial results indicates significant benefits for those suffering with this debilitating disease. This focus https://biotech220793.vidublog.com/40761365/firm-improves-cardiac-amyloidosis-treatment-with-the-therapy